BlackRock Inc. purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) dur

RADNOR, Pa., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics NASDAQ: MLYS said it is continuing commercial-launch preparations for lorundr

– PDUFA target date of December 22, 2026 for lorundrostat; commercial preparations on-track for laun

RADNOR, Pa., July 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid s

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a prot

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a prot

Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conferen

RADNOR, Pa. , June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a bioph

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

Late-breaking presentation reports a proteomic analysis of heart failure biomarkers during lorundros

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a biopharmaceutical company focused on developing medici

RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopha

– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront

Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chro

- Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically mea

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biophar

- Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontro

AstraZeneca wins FDA approvals for Baxfendy in hypertension and Enhertu in early HER2-positive breas

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the an

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the a

– The FDA assigned a PDUFA target action date of December 22, 2026 –– The NDA is based on positive d

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raise

– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants wi

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the a

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN t

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) w

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in pa

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight

Goldman Sachs analyst Richard Law maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and r

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS)

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse ra

Jefferies analyst Dennis Ding maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Hold and rais

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on de